TB2016 Presentations - Sunday 17 July 2016 (Session Room 12)


Evolution and spread of drug resistance – a slow moving process with great public health impact
Sebastien Gagneux, Swiss Tropical and Public Health Institute

Diagnosis of HIV-associated TB: Translating new knowledge and tools to maximise clinical impact
Robin Wood, Desmond Tutu HIV Centre, UCT

Better evidence, better policy
Yogan Pillay, National Department of Health, South Africa

Leaving no one behind – Key populations in TB
Lucica Ditiu, Stop TB Partnership

Abstract Session 3 - Transmission and Diagnosis

Abstract No. O17 Deterministic linkage to evaluate the burden of recurrent TB disease in Cape Town, South Africa
S. Hermans

Abstract No. O18 Mycobacterium tuberculosis molecular screening assay with sensitivity equivalent to culture
S. McFall

Abstract No. O20 Development of a multi-analyte panel for non-invasive pharmacokinetic monitoring of second-line anti-tuberculosis drugs in small hair samples
J. Metcalfe

Abstract No. O19 Diagnostic accuracy of Xpert®MTB/Rif, experience at district hospital of Buenos Aires for tuberculosis diagnosis
M. Gismondi

Breakout Session 7 - MDR/XDR TB

Evolution of drug resistance in KwaZulu-Natal and implications for TB control
Alex Pym, KwaZulu-Natal Research Institute for Tuberculosis and HIV

Advances in improving treatment outcomes for MDR/XDR TB
Gunar Günther, University of Namibia School of Medicine

Diagnostic advances in MDR/XDR TB and their impact on clinical outcomes
Susan Dorman, Johns Hopkins University

Decentralization of MDR-TB: A case study from South Africa
Virginia de Azavedo, City of Cape Town

Breakout Session 9 - Diagnostics and Biomarkers

Lessons from the rollout of Xpert MTB/RIF in South Africa
Wendy Stevens, National Health Laboratory Service South Africa

RePORT International: Advancing TB research using a common platform across global networks
Carol Hamilton, Duke University

Biomarkers with diagnostic accuracy in persons suspected for active TB
Jayne Sutherland, MRC Unit The Gambia

Novel biomarkers for monitoring treatment response
Gerhard Walzl, Stellenbosch University

Closing Session

Closing keynote
Trevor Mundel, Bill & Melinda Gates Foundation